In its first safety review, the independent Data Safety Monitoring Committee observed no data that would justify any changes to a Phase 3 clinical trial evaluating CytoDyn’s (OTCQB:CYDY) leronlimab in severely ill and critically ill COVID-19 patients. Consequently, it recommended that the study continue unmodified.
169 subjects are currently enrolled. A full interim analysis will be performed after 195 patients are enrolled per the protocol.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.